Research continues to power precision medicine, including: A first-in-class antibody drug conjugate for patients with ovarian cancer. First approval of a combination of two HER2 targeted therapeutics to treat patients with metastatic colon cancer. A new KRAS-targeted therapeutic for advanced or metastatic lung cancer. A new gene therapy-based immunotherapeutic for certain patients with bladder cancer. The first approval of an immune checkpoint inhibitor for pediatric and adult patients with a rare form of sarcoma. Four new T-cell engaging bispecific antibodies for patients with hematological malignancies. FDA APPROVALS IN TWO KEY CLASSES OF IMMUNOTHERAPEUTIC (As of July 31, 2023) 11 Immune Checkpoint Inhibitors to treat 20 types of cancer and any cancer with certain molecular features. 6 CAR T-cell therapies to treat a range of blood cancers. A Snapshot of a Year in Progress 1991 2020 Reduction In Overall Cancer Death Rate 33% 3.8 MILLION LIVES SAVED Reducing the Risk of Cancer Between August 1, 2022, and July 31, 2023, FDA approved: New anticancer therapeutics that are now benefiting patients with various types of cancer Previously approved anticancer therapeutics for treating new types of cancer New imaging agents 14 12 2 of all cancers in the U.S. are associated with preventable risk factors 40% 1965 2021 Cigarette Smoking Rates Among U.S. Adults 42% 11.5% 2020 1960-62 Prevalence of Obesity Among U.S. Adults 41.9% 12.5% AACR Cancer Progress Report 2023 10
RkJQdWJsaXNoZXIy NTkzMzk=